Shopping Cart 0
Cart Subtotal
USD 0

Retinopathy Of Prematurity - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Retinopathy Of Prematurity-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity-Pipeline Review, H2 2018, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births..

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 7 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinopathy Of Prematurity-Overview

Retinopathy Of Prematurity-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinopathy Of Prematurity-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinopathy Of Prematurity-Companies Involved in Therapeutics Development

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Insmed Inc

Protheragen Inc

Recordati SpA

Retinopathy Of Prematurity-Drug Profiles

Drug for Retinopathy of Prematurity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SCG3 for Diabetic Retinopathy and Retinopathy of Prematurity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuroprotectin D1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propranolol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Retinopathy of Prematurity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinopathy Of Prematurity-Dormant Projects

Retinopathy Of Prematurity-Product Development Milestones

Featured News & Press Releases

Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Retinopathy Of Prematurity, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Retinopathy Of Prematurity, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Retinopathy Of Prematurity-Pipeline by D. Western Therapeutics Institute Inc, H2 2018

Retinopathy Of Prematurity-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Retinopathy Of Prematurity-Pipeline by Insmed Inc, H2 2018

Retinopathy Of Prematurity-Pipeline by Protheragen Inc, H2 2018

Retinopathy Of Prematurity-Pipeline by Recordati SpA, H2 2018

Retinopathy Of Prematurity-Dormant Projects, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Retinopathy Of Prematurity Therapeutic Products under Development, Key Players in Retinopathy Of Prematurity Therapeutics, Retinopathy Of Prematurity Pipeline Overview, Retinopathy Of Prematurity Pipeline, Retinopathy Of Prematurity Pipeline Assessment


Companies

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Insmed Inc

Protheragen Inc

Recordati SpA